Cambium Bio Ltd · ASX:CMB
Cambium Bio — Investor Presentation (September 2026)
29 slides from Cambium Bio's investor presentation, Sep 30, 2026
Slide 1: ASX Announcement: CEO presentation at ShareCafe and FNN webinar
ASX Announcement 30 September 2026 For personal use only Cambium CEO, Karolis Rosickas presentation at ShareCafe and Finance News Network (FNN) Sydney, Australia, 30 September 2026: Cambium Bio Limited (ASX:CMB) (“Cambium Bio” or “Company”) is pleased to advice our Chief Executive Officer, Karolis R
Slide 2: Corporate Presentation September 2026
For personal use only C O R P O R AT E P R E S E N T AT I O N · S E P T E M B E R 2026 A late-stage biologic for dry eye disease, built on a proprietary regenerative platform Cambium Bio Limited ASX: CMB
Slide 3: Disclaimer
Disclaimer Summary information Future performance For personal use only This Presentation contains summary information about the current activities of Cambium Bio Limited This Presentation contains certain "forward-looking statements". These statements are based on current (ASX: CMB) ("Cambium Bio"
Slide 4: A Phase 3-ready biologic built on a commercial platform
A Phase 3-ready biologic built on a commercial platform Overview Human platelet lysate (HPL) products For personal use only Cambium Bio Limited (CBL) is a late clinical-stage regenerative medicine company Listed on the Australian Securities Exchange (ASX) Proprietary technology platform based on fib
Slide 5: A founder-scientist with clinical, CMC and finance leads
A founder-scientist with clinical, CMC and finance leads Executive team For personal use only Dr Edmund Waller Karolis Rosickas Dr Neera Jagirdar Dennis Hannigan MD, PhD MS, MBA MD, MPH MS Chief Scientific Officer; Chief Executive Officer VP, Clinical Development VP, CMC and Quality Board Chair Foun
Slide 6: Directors with ophthalmology and platelet biologics depth
Directors with ophthalmology and platelet biologics depth Non-Executive Directors For personal use only Dr Sebastian A/Prof Denese C Terence Walts A/Prof Chandra Bala MBA Tseng Marks MBBS, PhD, FRANZCO DDS, MBA PhD Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Di
Slide 7: Agenda
01 For personal use only Market opportunity 01 Market opportunity 02 Elate Ocular® and Aurarix® 03 Phase 1/2 clinical data 04 Pivotal Phase 3 trial 05 Exclusivity and value
Slide 8: Dry eye is a multi-factor loss of tear film homeostasis
Dry eye is a multi-factor loss of tear film homeostasis For personal use only Definition and clinical presentation DED (keratoconjunctivitis sicca) is a multi-factor disorder of tears and ocular surface Loss of tear film homeostasis: failure to produce high-quality or sufficient tears May lead to vi
Slide 9: Most dry eye patients never receive prescription therapy, and most who start, stop
Most dry eye patients never receive prescription therapy, and most who start, stop For personal use only A large population that never reaches treatment… …and current drugs fail to keep those who start 93% of diagnosed US patients receive no prescription therapy³ ~90% stop their first prescription w
Slide 10: Approved therapies force a trade-off between speed, tolerability and symptom relief
Approved therapies force a trade-off between speed, tolerability and symptom relief For personal use only Product Approved Mechanism Label indication First significant effect in pivotal trials Most common adverse reaction 2 wk 1 mo 3 mo 6 mo Calcineurin inhibitor (cyclosporine Signs only (tear Ocula
Slide 11: Elate Ocular and the Aurarix platform
02 For personal use only Elate Ocular® and the Aurarix® platform 01 Market opportunity 02 Elate Ocular® and Aurarix® 03 Phase 1/2 clinical data 04 Pivotal Phase 3 trial 05 Exclusivity and value
Slide 12: Elate Ocular: a potential best-in-class biologic for dry eye disease
Elate Ocular®: a potential best-in-class biologic for dry eye disease "Off the shelf natural tear" For personal use only SOURC E Derived from enriched, fibrinogen-depleted human platelet lysate CO M P O S I T I O N Contains growth factors (EGF, PDGF, TGF-β1), proteins and minerals at levels comparab
Slide 13: Aurarix: a standardised, scalable platelet-lysate platform
Aurarix®: a standardised, scalable platelet-lysate platform Fibrinogen-depleted human platelet lysate platform technology For personal use only What it is Aurarix® is a pooled, enriched, fibrinogen-depleted, allogeneic human platelet lysate (FD-HPL) sourced from healthy donors; an off-the-shelf biol
Slide 14: Elate Ocular is comparable in composition to natural tears and autologous serum tears
Elate Ocular® is comparable in composition to natural tears and to autologous serum tears, an established therapy For personal use only Natural tears Autologous serum tears Elate Ocular® Components found in each pH 7.4 7.4 7.7 Osmolality mOsm/kg 298 296 284 EGF key active, ng/mL as instilled 0.2–3.0
Slide 15: Four decades of serum tear research, now without the blood draw
Four decades of serum tear research, now without the blood draw For personal use only Autologous serum tears Elate Ocular® Source Patient's own blood: about 100 mL drawn every 1–3 months Pooled, screened donor platelets; no blood draw for the patient Compounded per patient; dispatched only after ser
Slide 16: Phase 1/2 clinical data
03 For personal use only Phase 1/2 clinical data 01 Market opportunity 02 Elate Ocular® and Aurarix® 03 Phase 1/2 clinical data 04 Pivotal Phase 3 trial 05 Exclusivity and value
Slide 17: Phase 1/2: safe and well tolerated at both doses
Phase 1/2: safe and well tolerated at both doses Randomised, double-masked, vehicle-controlled trial in severe dry eye secondary to chronic ocular graft-versus-host disease For personal use only 64 9 1:1:1 QID, 42 days Safety patients with severe dry eye from US sites, under FDA IND 17669 randomised
Slide 18: Elate Ocular 30% reduced dry eye symptoms versus vehicle
Elate Ocular® 30% reduced dry eye symptoms versus vehicle Phase 1/2 efficacy: difference from vehicle in change from baseline to Day 42, with 95% confidence intervals For personal use only Symptom (0–100 scale) Difference vs vehicle (95% CI) Difference (95% CI) p-value Eye discomfort −33.0 (−50.6 to
Slide 19: Sign outcomes favoured Elate Ocular 30%
Sign outcomes favoured Elate Ocular® 30% Phase 1/2 efficacy: difference from vehicle at Day 42, with 95% confidence interval For personal use only Investigator's global evaluation 0–6 scale; lower = better Tear break-up time Seconds; higher = better DIFFERENCE VS VEHICLE DIFFERENCE VS VEHICLE −1.17
Slide 20: Elate Ocular outperforms approved dry eye disease therapies in symptom relief
Elate Ocular® outperforms approved dry eye disease therapies in symptom relief Elate Ocular® demonstrates best-in-class improvement in clinically meaningful eye discomfort and dryness endpoints For personal use only Drug Study Symptom endpoint Placebo-adjusted treatment effect size (%)* p-value Dura
Slide 21: Pivotal Phase 3 trial
04 For personal use only Pivotal Phase 3 trial 01 Market opportunity 02 Elate Ocular® and Aurarix® 03 Phase 1/2 clinical data 04 Pivotal Phase 3 trial 05 Exclusivity and value
Slide 22: CAMOMILE-2: one registration-enabling Phase 3 trial
CAMOMILE-2: one registration-enabling Phase 3 trial Multicentre, 1:1 randomised, double-masked, vehicle-controlled trial in moderate to severe dry eye, followed by a 12-month safety extension For personal use only 515 1:1 11 9 weeks patients enrolled; 475 evaluable Elate Ocular® vs vehicle, double-
Slide 23: CAMOMILE-2: planned sites across Australia and the US
CAMOMILE-2: 11 planned sites across Australia and the US Indicative site network with experienced dry eye investigators; site contracts yet to be executed For personal use only Australia 8 sites in 4 states United States 3 sites in 3 states Lexington, KY Kentucky Eye Institute 1 1 Brisbane 1 QUT (Ke
Slide 24: A clear path to BLA submission in 2028
A clear path to BLA submission in 2028 One registration-enabling Phase 3 trial in dry eye disease For personal use only CO MPL ET ED Obtained an Investigational New Drug (IND) application approval from the FDA to initiate the Phase 3 trial Retained a Contract Development and Manufacturing Organisati
Slide 25: Exclusivity and value realisation
05 For personal use only Exclusivity and value realisation 01 Market opportunity 02 Elate Ocular® and Aurarix® 03 Phase 1/2 clinical data 04 Pivotal Phase 3 trial 05 Exclusivity and value
Slide 26: Multi-layered exclusivity protects Elate Ocular into the 40s
Multi-layered exclusivity protects Elate Ocular® into the 2040s Composition patent, regulatory exclusivity and analytical barrier compound to create a durable commercial moat For personal use only Composition and manufacturing patent 12-year BPCIA exclusivity (US) High biosimilarity barrier US 9,688
Slide 27: Dry eye deals reach up to US$5.3BN, several at Phase 3
Dry eye deals reach up to US$5.3BN, several at Phase 3 Dry eye companies and drugs have been taken out at Phase 3 or registration stages at significant valuations For personal use only Select M&A and licensing transactions in dry eye disease Date May 2019 December 2019 November 2022 November 2022 Ju
Slide 28: Investment highlights
Investment highlights For personal use only 1 Large addressable market Dry eye disease affects 16.4M diagnosed US adults, a 6.8% prevalence that continues to rise Over US$2BN in annual US prescription drug expenditure, expanding with new approvals 2 Unmet need Only ~7% of 16.4M diagnosed US patients
Slide 29: Contact details
For personal use only CO N TA C T D E TA I LS Karolis Rosickas Chief Executive Officer kr@cambium.bio Cambium Bio Limited · ASX: CMB www.cambium.bio · +61 485 035 821 · ABN 13 127 035 358 Unit 2.06/31 Lexington Drive, Bella Vista NSW 2153, Australia